IDXX Stock Analysis: IDEXX Laboratories | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 44.001m USD | 12M Return: 4.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 383M
EPS Trend: 99.4%
Qual. Beats: 0
Rev. Trend: 98.7%
Qual. Beats: 4
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
IDEXX Laboratories is a U.S.-headquartered diagnostics company operating across three segments: Companion Animal Group, Water Quality Products, and Livestock, Poultry and Dairy. Its business is anchored in the veterinary diagnostics market, which has expanded alongside rising pet ownership and increased spending on animal healthcare. Classified within the Health Care Equipment sub-industry, IDEXX is a leading provider of in-clinic diagnostic platforms for veterinarians.
The companys offerings span point-of-care analyzers for blood, urine, and hematology testing, SNAP rapid assay kits, commercial reference laboratory services, and telemedicine/advisory consultations for veterinarians. In water testing, IDEXX supplies coliform and E. coli detection products such as Colilert and Quanti-Tray, serving municipal water utilities and private testing labs. The Livestock, Poultry and Dairy segment provides herd and flock health diagnostic tests and instrumentation.
IDEXX complements its instruments with veterinary practice software, cloud-based patient data platforms (VetConnect PLUS), and the VetLab Station workflow system. Products are sold through direct sales, customer service, and technical support teams as well as independent distributors. The company was incorporated in 1983, is headquartered in Westbrook, Maine, and has been publicly traded on NASDAQ since 1991.
- Companion Animal Group segment drives revenue and margin expansion
- Diagnostic consumables and reference lab services boost recurring revenue
- International veterinary market expansion accelerates top-line growth
| Net Income: 1.10b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.32 > 0.02 and ΔFCF/TA 5.83 > 1.0 |
| NWC/Revenue: 3.47% < 20% (prev 4.61%; Δ -1.14% < -1%) |
| CFO/TA 0.36 > 3% & CFO 1.21b > Net Income 1.10b |
| Net Debt (1.03b) to EBITDA (1.56b): 0.66 < 3 |
| Current Ratio: 1.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (80.7m) vs 12m ago -1.52% < -2% |
| Gross Margin: 62.05% > 18% (prev 61.32%; Δ 0.73% > 0.5%) |
| Asset Turnover: 134.7% > 50% (prev 122.3%; Δ 12.40% > 0%) |
| Interest Coverage Ratio: 35.04 > 6 (EBIT TTM 1.41b / Interest Expense TTM 40.2m) |
| A: 0.05 (Total Current Assets 1.45b - Total Current Liabilities 1.30b) / Total Assets 3.39b |
| B: 1.97 (Retained Earnings 6.67b / Total Assets 3.39b) |
| C: 0.43 (EBIT TTM 1.41b / Avg Total Assets 3.30b) |
| D: 0.85 (Book Value of Equity 1.56b / Total Liabilities 1.83b) |
| Altman-Z'' = 10.49 = AAA |
| DSRI: 1.02 (Receivables 697.2m/604.2m, Revenue 4.45b/3.93b) |
| GMI: 0.99 (GM 61.32% / 62.05%) |
| AQI: 0.96 (AQ_t 0.32 / AQ_t-1 0.33) |
| SGI: 1.13 (Revenue 4.45b / 3.93b) |
| TATA: -0.03 (NI 1.10b - CFO 1.21b) / TA 3.39b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 563.57 with a total of 589,349 shares traded. Over the past week, the price has changed by +1.03%, over one month by +1.19%, over three months by +0.10% and over the past year by +4.15%.
Current recommended Stop Loss: 535.60 (which is 5% or 1.6 ATR below the current price).
IDEXX Laboratories has received a consensus analysts rating of 3.62. Therefore, it is recommended to hold IDXX.
- StrongBuy: 3
- Buy: 3
- Hold: 6
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 709.1 | 25.8% |
P/E Trailing = 40.9846
P/E Forward = 37.8788
P/S = 9.8965
P/B = 28.2764
P/EG = 3.5744
Revenue TTM = 4.45b USD
EBIT TTM = 1.41b USD
EBITDA TTM = 1.56b USD
Long Term Debt = 299.9m USD (from longTermDebt, last quarter)
Short Term Debt = 706.9m USD (from shortTermDebt, last quarter)
Debt = 1.23b USD (from shortLongTermDebtTotal, last quarter) + Leases 125.6m
Net Debt = 1.03b USD (calculated: Debt 1.23b - CCE 200.5m)
Enterprise Value = 45.0b USD (44.0b + Debt 1.23b - CCE 200.5m)
Interest Coverage Ratio = 35.04 (Ebit TTM 1.41b / Interest Expense TTM 40.2m)
EV/FCF = 41.71x (Enterprise Value 45.0b / FCF TTM 1.08b)
FCF Yield = 2.40% (FCF TTM 1.08b / Enterprise Value 45.0b)
FCF Margin = 24.28% (FCF TTM 1.08b / Revenue TTM 4.45b)
Net Margin = 24.63% (Net Income TTM 1.10b / Revenue TTM 4.45b)
Gross Margin = 62.05% ((Revenue TTM 4.45b - Cost of Revenue TTM 1.69b) / Revenue TTM)
Gross Margin QoQ = 63.35% (prev 60.35%)
Tobins Q-Ratio = 13.30 (Enterprise Value 45.0b / Total Assets 3.39b)
Interest Expense / Debt = 3.27% (Interest Expense 40.2m / Debt 1.23b)
Taxrate = 20.03% (274.3m / 1.37b)
NOPAT = 1.13b (EBIT 1.41b * (1 - 20.03%))
Current Ratio = 1.12 (Total Current Assets 1.45b / Total Current Liabilities 1.30b)
Debt / Equity = 0.79 (Debt 1.23b / totalStockholderEquity, last quarter 1.56b)
Debt / EBITDA = 0.66 (Net Debt 1.03b / EBITDA 1.56b)
Debt / FCF = 0.95 (Net Debt 1.03b / FCF TTM 1.08b)
Total Stockholder Equity = 1.55b (last 4 quarters mean from totalStockholderEquity)
RoA = 33.19% (Net Income 1.10b / Total Assets 3.39b)
RoE = 70.87% (Net Income TTM 1.10b / Total Stockholder Equity 1.55b)
RoCE = 76.40% (EBIT 1.41b / Capital Employed (Equity 1.55b + L.T.Debt 299.9m))
RoIC = 43.50% (NOPAT 1.13b / Invested Capital 2.59b)
WACC = 8.22% (E(44.0b)/V(45.2b) * Re(8.38%) + D(1.23b)/V(45.2b) * Rd(3.27%) * (1-Tc(0.20)))
Discount Rate = 8.38% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -90.80 | Cagr: -1.74%
[DCF] Terminal Value 77.97% ; FCFF base≈982.9m ; Y1≈1.13b ; Y5≈1.66b
[DCF] Fair Price = 303.3 (EV 25.0b - Net Debt 1.03b = Equity 23.9b / Shares 78.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.40 | EPS CAGR: 13.68% | SUE: 0.78 | # QB: 0
Revenue Correlation: 98.68 | Revenue CAGR: 8.24% | SUE: 1.80 | # QB: 4
EPS current Quarter (2026-06-30): EPS=3.94 | Chg30d=+0.45% | Revisions=+0% | Analysts=12
EPS next Quarter (2026-09-30): EPS=3.78 | Chg30d=+0.28% | Revisions=+44% | Analysts=11
EPS current Year (2026-12-31): EPS=14.63 | Chg30d=+0.80% | Revisions=+62% | GrowthEPS=+11.8% | GrowthRev=+9.3%
EPS next Year (2027-12-31): EPS=16.52 | Chg30d=+0.72% | Revisions=+62% | GrowthEPS=+12.9% | GrowthRev=+8.7%
[Analyst] Revisions Ratio: +57% (up=26, down=6)